Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 7/20 | 0.47 |
| ▸ | FLT3 | P36888 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 6/20 | 0.39 |
| ▸ | CA1 | P00915 | 6/20 | 0.39 |
| ▸ | CA2 | P00918 | 6/20 | 0.39 |
| ▸ | CA9 | Q16790 | 6/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | TEK | Q02763 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13020121 | 0.88 | ADK (0.49) | ADKFLT3KDM4EALDH1A1HTT | |
| SCHEMBL3789169 | 0.86 | KDM4E (0.54) | ADKFLT3KDM4EALDH1A1HTT | |
| SCHEMBL13020030 | 0.85 | ADK (0.52) | ADKFLT3KDM4EALDH1A1HTT | |
| SCHEMBL13020106 | 0.83 | ADK (0.49) | ADKFLT3KDM4EALDH1A1HTT | |
| SCHEMBL13020139 | 0.82 | GSK3B (0.49) | ADKFLT3KDM4EALDH1A1HTT | |
| SCHEMBL13020031 | 0.82 | ADK (0.54) | ADKFLT3KDM4EALDH1A1HTT | |
| SCHEMBL13020080 | 0.81 | ADK (0.47) | ADKFLT3KDM4EALDH1A1HTT | |
| SCHEMBL13020081 | 0.80 | ADK (0.46) | ADKFLT3KDM4EALDH1A1HTT | |
| SCHEMBL3784312 | 0.78 | CA12 (0.47) | ADKALDH1A1CA12CA1CA2 | |
| SCHEMBL3788058 | 0.73 | KDM4E (0.54) | ADKFLT3KDM4EALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | RAB1A, COPB1, GOLT1B | ADK 3845/4885FLT3 4342/4885KDM4E 4425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.